HomeMarkets Markets Biogen advances Alzheimer’s drug to late-stage trial despite disappointing data By Ilene May 14, 2026 0 209 FacebookTwitterPinterestWhatsApp Biogen plans to advance an experimental drug for Alzheimer’s disease to late-stage testing despite disappointing mid-stage trial data, the company …This post was originally published on this site Share FacebookTwitterPinterestWhatsApp Subscribe Login Notify of new follow-up comments new replies to my comments Please login to comment 0 Comments Inline Feedbacks View all comments Stay Connected148,415FansLike396,312FollowersFollow3,740SubscribersSubscribe Latest Articles Hot Items How Trump Is Selling Out Ukraine (shared) Market News Fed Interest Rate Hike Seems More Likely This Month After Alarming Inflation Data Markets Unbiased Stock Market Insights: How to Separate Evidence from Noise in 2026 Energy Houthis reportedly strike Saudi national oil company headquarters Market News Operation Vivaldi: success of Ukraine’s counteroffensive shows it has learned to manoeuvre on a drone-filled battlefield Markets Inflation worsened last month to 3.7% in sign that prices remain elevated as midterm elections near Markets Which Way Wednesday – Early Earnings Offer Clues to Market Direction AI Across the US, people don’t want data centers coming to their communities Market News Why the Paramount-Warner merger is a problem for democracy Market News The Forces Driving Up Bond Yields Take a Troubling Turn (shared) Energy Inside Trump, Netanyahu’s dilemma: Strike Iran before elections or wait Markets Trading Ideas Subscription Service: How to Choose One in 2026 Market News Choose Your Overlord (shared) Markets PhilStockWorld October Portfolio Review (Members Only) Load more